NASDAQ:DVAX
Dynavax Technologies Corporation Stock News
$11.08
-0.0800 (-0.717%)
At Close: Jul 02, 2024
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
04:09pm, Thursday, 27'th Jun 2024
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax to Present at Upcoming Investor Conferences
04:18pm, Tuesday, 28'th May 2024
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t
Natixis Advisors L.P. Buys 1,804 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
04:58am, Monday, 20'th May 2024
Natixis Advisors L.P. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Ex
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
08:39am, Tuesday, 14'th May 2024
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
08:30am, Tuesday, 14'th May 2024
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sB
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
07:51pm, Wednesday, 08'th May 2024
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer -
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
06:21pm, Wednesday, 08'th May 2024
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago.
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
04:01pm, Wednesday, 08'th May 2024
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
04:05pm, Wednesday, 24'th Apr 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi
Dynavax Technologies: Still A Believer
07:39am, Sunday, 24'th Mar 2024
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
06:54pm, Tuesday, 27'th Feb 2024
EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
07:34pm, Thursday, 22'nd Feb 2024
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
06:16pm, Thursday, 22'nd Feb 2024
Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago.
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
04:01pm, Thursday, 22'nd Feb 2024
HEPLISAV-B ® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expec
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
04:15pm, Thursday, 08'th Feb 2024
EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will